Company intelligence / Profile preview

Servest

Suresnes, Île-de-France, Franceservest.co.za ↗

Ownership: Private
Employees: ~22000
Development stage: Commercial

Overview

Servier is a global pharmaceutical group focused on oncology, cardiometabolism & venous diseases, neurology, and rare diseases. The company has five approved oncology medicines in the U.S., including the first targeted therapy for IDH-mutant glioma. It invests heavily in R&D (~20% of revenue from brand-name medicines) and has a robust pipeline spanning early to late clinical stages.

Therapeutic areas: OncologyCardiovascularRare DiseasesNeurology
Modalities: Small moleculeMonoclonal antibodyBiologic
Industry: Pharma

Partnerships

Numerous alliances with academic researchers, start-ups, pharma groups and biotech companies for open innovation; specific partners not listed by name

Beyond the preview

Go deeper on Servest.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Servest.

Explore the full profile